Arvinas Alternatives & Competitors
12 companies similar to Arvinas — Leading the way in targeted protein degradation therapeutics
Companies similar to Arvinas
China
Precigen
Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of ge...
Germantown, United States
Captor Therapeutics SA
Captor Therapeutics aims to treat cancer, infections, and diseases by targeting the diffic...
Poland
Orum Therapeutics
A public biotechnology company pioneering a novel class of protein degraders.
Lexington, United States
Track all Arvinas competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Forma Therapeutics
Dedicated to transforming the lives of patients with rare hematologic diseases and cancers...
Watertown, United States
Cullgen Inc.
Powering protein degradation for tomorrow's medicines
San Diego, United States
HAVAH Therapeutics
Developing prevention and early treatment options for hormonally driven breast cancer and...
Australia
Lisata Therapeutics, Inc.
Targeted Therapy Delivered
United States
Monte Rosa Therapeutics
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly select...
Boston, United States
Zevra Therapeutics
A Rare Approach to Therapeutics
Celebration, United State...
Dynacure
Dynacure develops new treatments for orphan disorders, focusing on CNM through Dyn101 prog...
Illkirch-graffenstaden, F...
Frontier Medicines
Frontier Medicines is a biopharmaceutical company that “drugs the undruggable” to transfor...
South San Francisco, Unit...
About Arvinas
Arvinas is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in the United States. The company is committed to developing targeted protein degradation therapeutics with the aim of improving the lives of patients suffering from debilitating and life-threatening diseases. Their proprietary PROT...
Biopharmaceutical, Protein Degradation, Therapeutics, Clinical-stage, Disease Treatment, PROTAC® Discovery Engine Platform, Proteolysis Targeting Chimeras, Metastatic Castrate-resistant Prostate Cancer, Locally Advanced Breast Cancer, Metastatic ER+/HER2- Breast Cancer, Drug Discovery, Autoimmune Diseases, Rare Diseases, Cancer Therapy, Preclinical Pipeline
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Arvinas and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Arvinas on 9 Jun 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 20 Sep 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
